The company plans to raise funds via Initial Public offerings through fresh issue aggregating up to Rs. 390 crores (The “Fresh Issue”) and an “Offer for Sale (OFS)” comprising up to 39,100,000 equity shares
Healthium Medtech, global medtech company focused on products used in surgical, post-surgical and chronic care, has filed its Draft Red Herring Prospectus (“DRHP”) with market regulator Securities and Exchange Board of India (“SEBI”).
The company plans to raise funds via Initial Public offerings through fresh issue aggregating up to Rs. 390 crores (The “Fresh Issue”) and an “Offer for Sale (OFS)” comprising up to 39,100,000 equity shares. The OFS comprises upto 39,000,000 equity shares by Quinag Acquisition (FDI) Limited (“Promoter Selling Shareholders”) and up to 100,000 equity shares by Mahadevan Naryanamoni (“Individual Selling Shareholder”).
Healthium Medtech operates across three key markets, namely, India, UK and rest of the world and four focus areas, namely, advanced surgery, urology, arthroscopy and wound care.
The company proposes to utilise net proceed from the issue towards funding
- repayment and/or pre-payment, in full or part, of certain borrowings availed by company;
- Investment into subsidiaries, Sironix Medical Technologies B.V. (“Sironix”), Clinisupplies Limited (“Clinisupplies”) and Quality Needles Private Limited (“Quality Needles”);
- Acquisitions and other strategic initiatives; and (iv) General corporate purposes